Hikari Power Ltd lessened its holdings in Amgen, Inc. (NASDAQ:AMGN) by 29.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 34,130 shares of the medical research company’s stock after selling 14,000 shares during the period. Hikari Power Ltd’s holdings in Amgen were worth $7,075,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also made changes to their positions in AMGN. Kwmg LLC purchased a new stake in shares of Amgen in the second quarter valued at about $108,000. Mainstay Capital Management LLC ADV purchased a new position in shares of Amgen during the second quarter valued at approximately $111,000. Polaris Greystone Financial Group LLC purchased a new position in shares of Amgen during the third quarter valued at approximately $166,000. Dixon Hubard Feinour & Brown Inc. VA purchased a new position in shares of Amgen during the second quarter valued at approximately $200,000. Finally, Family Firm Inc. purchased a new position in shares of Amgen during the second quarter valued at approximately $202,000. 82.37% of the stock is currently owned by institutional investors.
Shares of AMGN stock opened at $189.92 on Tuesday. Amgen, Inc. has a one year low of $163.31 and a one year high of $210.19. The company has a quick ratio of 2.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.05. The company has a market cap of $119.20 billion, a P/E ratio of 15.10, a P/E/G ratio of 1.95 and a beta of 1.37.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, October 30th. The medical research company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.45 by $0.24. Amgen had a net margin of 9.44% and a return on equity of 54.14%. The firm had revenue of $5.90 billion during the quarter, compared to analyst estimates of $5.78 billion. During the same quarter in the prior year, the business posted $3.27 earnings per share. Amgen’s revenue for the quarter was up 2.3% compared to the same quarter last year. Research analysts anticipate that Amgen, Inc. will post 14.21 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 7th. Investors of record on Friday, November 16th will be given a dividend of $1.32 per share. This represents a $5.28 annualized dividend and a yield of 2.78%. The ex-dividend date is Thursday, November 15th. Amgen’s dividend payout ratio (DPR) is 41.97%.
AMGN has been the topic of several recent analyst reports. BidaskClub raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, July 11th. Morgan Stanley upped their price objective on shares of Amgen from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Friday, July 13th. Jefferies Financial Group reissued a “buy” rating and set a $200.00 price objective on shares of Amgen in a research note on Monday, July 16th. Zacks Investment Research downgraded shares of Amgen from a “buy” rating to a “hold” rating in a research note on Tuesday, July 17th. Finally, Piper Jaffray Companies upped their price objective on shares of Amgen from $190.00 to $210.00 and gave the company an “overweight” rating in a research note on Thursday, July 26th. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $204.55.
COPYRIGHT VIOLATION WARNING: “Hikari Power Ltd Sells 14,000 Shares of Amgen, Inc. (AMGN)” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/11/06/hikari-power-ltd-sells-14000-shares-of-amgen-inc-amgn.html.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
See Also: Price to Earnings Ratio (PE) Basics
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.